

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6042736

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
MILLENNIUM PHARMACEUTICALS, INC.	02/03/2020
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	DOT THERAPEUTICS-1, INC.
<b>Street Address:</b>	2765 SAND HILL ROAD
<b>City:</b>	MENLO PARK
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	94025
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	12164762
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(650)493-6811
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6504615211
<b>Email:</b>	cricks@wsgr.com
<b>Correspondent Name:</b>	CHRISTINE RICKS
<b>Address Line 1:</b>	650 PAGE MILL ROAD
<b>Address Line 4:</b>	PALO ALTO, CALIFORNIA 94304-1050
<b>ATTORNEY DOCKET NUMBER:</b>	57841-701.201
<b>NAME OF SUBMITTER:</b>	CHRISTINE RICKS
<b>SIGNATURE:</b>	/Christine Ricks/
<b>DATE SIGNED:</b>	04/01/2020
<b>Total Attachments: 15</b>	
source=57841_701_201_Millennium_to_DOT_signed_assignment#page1.tif	
source=57841_701_201_Millennium_to_DOT_signed_assignment#page2.tif	
source=57841_701_201_Millennium_to_DOT_signed_assignment#page3.tif	
source=57841_701_201_Millennium_to_DOT_signed_assignment#page4.tif	
source=57841_701_201_Millennium_to_DOT_signed_assignment#page5.tif	
source=57841_701_201_Millennium_to_DOT_signed_assignment#page6.tif	

source=57841\_701\_201\_Millennium\_to\_DOT\_signed\_assignment#page7.tif  
source=57841\_701\_201\_Millennium\_to\_DOT\_signed\_assignment#page8.tif  
source=57841\_701\_201\_Millennium\_to\_DOT\_signed\_assignment#page9.tif  
source=57841\_701\_201\_Millennium\_to\_DOT\_signed\_assignment#page10.tif  
source=57841\_701\_201\_Millennium\_to\_DOT\_signed\_assignment#page11.tif  
source=57841\_701\_201\_Millennium\_to\_DOT\_signed\_assignment#page12.tif  
source=57841\_701\_201\_Millennium\_to\_DOT\_signed\_assignment#page13.tif  
source=57841\_701\_201\_Millennium\_to\_DOT\_signed\_assignment#page14.tif  
source=57841\_701\_201\_Millennium\_to\_DOT\_signed\_assignment#page15.tif

## ASSIGNMENT

WHEREAS, MILLENNIUM PHARMACEUTICALS, INC. (hereinafter "ASSIGNOR") of 40 LANDSDOWNE STREET, CAMBRIDGE, MA 02139, is aware of the patents and patent applications listed on Exhibit A attached hereto:

WHEREAS, DOT THERAPEUTICS-1, INC. (hereinafter "ASSIGNEE"), having a place of business at 2765 SAND HILL ROAD MENLO PARK, CA 94025, desires to acquire or confirm an interest therein;

NOW, THEREFORE, to all whom it may concern, be it known that, in consideration of agreements previously and duly entered into between the parties, and/or for other good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR hereby confirms and/or declares that it has sold, assigned, transferred, and conveyed and/or does hereby sell, assign, transfer and convey unto said ASSIGNEE, its successors, assigns, and legal representatives, its entire right, title, and interest in and throughout the United States of America, its territories, and all foreign countries, in and to the patents and patent applications listed on Exhibit A attached hereto, any and all inventions described therein, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, including in and to any application that is based in whole or in part on any of the Patents, including to divisional, continuing, continuation-in-part, substitute, renewal, reissue, reexamination, and any other applications or extension of any kind of any of the foregoing, for example, that claim priority to any such patent applications and patents, and patent applications and patents which have or which may be filed thereon or may be granted therefor, including any and all counterparts worldwide (hereinafter "Patents"); and hereby confirms that such sale, assignment, transfer and conveyance is and was effective as of December 16, 2019. ASSIGNOR'S sale, assignment, transfer, and conveyance applies to all right, title and interest in and to each of the Patents, including all right, title and interest in and to all income, royalties, damages and payments now or hereafter due or payable with respect to the Patents, and all causes of action (whether in law or equity) and the right to sue, counterclaim, and recover for the past, present and future infringement of the Patents. Also, this sale, assignment and transfer pertains to and includes any and all other rights arising under or pursuant to any and all domestic and international agreements, treaties, or laws relating to the protection of industrial property, including all rights to claim priority to and from the Patents, including all rights of priority under the International Convention for the Protection of Industrial Property, and in and to any such patent(s) as may issue or reissue thereon including any and all original and reissued patents which have been or shall be issued in the United States and foreign countries; said inventions, applications, and patent(s) to be held and enjoyed by ASSIGNEE for its own use and for its successors, assigns and legal representatives, to the full end of the term for which said patent(s) may be granted as fully and entirely as the same would have been held by ASSIGNOR had this sale, assignment and transfer not been made:

AND, ASSIGNOR hereby acknowledges that this Assignment, being of its entire right, title, and interest in and to the inventions, carries with it the right in ASSIGNEE, by attorneys and agents of ASSIGNEE selection, to apply for and receive any and all patent(s) for said inventions in its own name:

AND, ASSIGNOR hereby further agrees for itself and its executors and administrators to cooperate with ASSIGNEE to enable ASSIGNEE to enjoy to the fullest extent the right, title, and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by ASSIGNOR includes the execution upon request of any other lawful documents and likewise the performance of any other lawful acts which may be deemed necessary to perfect and secure fully the Patents and right, title, and interests herein confirmed and/or declared, and/or

sold, assigned, transferred and conveyed to ASSIGNEE, its successors, assignees, and legal representatives, but at its expense and charges, including the filing and prosecution of any of the patent applications included in the Patents, the filing and prosecution of applications for patents in foreign countries, the filing and prosecution of substitution, reissue, divisional, continuation, or additional applications covering the inventions, the execution of petitions, oaths, specifications, declarations, or other papers, the prompt production of pertinent facts and documents, the giving of testimony, preliminary statements, other statements, or other assistance in any interference or other proceeding in which the inventions or any applications or patents directed to the inventions may be involved, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions, by communicating to the ASSIGNEE all facts ASSIGNOR knows relating to the inventions and their history, and generally by doing everything possible which ASSIGNEE shall consider desirable for aiding in securing and maintaining proper patent protection for the inventions and for vesting title in the inventions and all applications for patent and all patents on the inventions in ASSIGNEE:

AND, ASSIGNOR further hereby authorizes ASSIGNEE or its attorneys or agents to insert the correct serial number(s) and/or filing date(s) into this assignment document, if appropriate:


AND, ASSIGNOR hereby requests the Director of Patents and Trademarks of the United States, and any official of any country or countries whose duty it is to issue patents or other evidence or forms of industrial property protection, to issue any and all patent(s) as shall be granted upon said application or applications based thereon to ASSIGNEE, its successors, assigns, and legal representatives, for the sole use of said ASSIGNEE, its successors, assigns, and legal representatives:

AND, ASSIGNOR covenants with said ASSIGNEE that no assignment, grant, mortgage, license, contract, or other agreement affecting the rights and property herein conveyed has been made or will be made to others by ASSIGNOR, and that full right to convey the same as herein expressed is possessed by ASSIGNOR.

IN TESTIMONY WHEREOF, ASSIGNOR by its duly authorized representative acting on his own free will have caused this instrument to be duly executed and have hereunto set his hand and affixed his seal on the dates set forth below.


SIGNED this 3rd day of February 2020.

MILLENNIUM PHARMACEUTICALS, INC.

By:   
Name: Constance Yeung  
Title: VP, IP Region Head

RECEIVED AND AGREED TO BY ASSIGNEE:

DOT THERAPEUTICS-1, INC.

By:   
Name: Mike Grant  
Title: CEO


State of Massachusetts       )  
  )     ss.  
County of Middlesex        )

On February 3, 2020, before me, Ann E. Sherry, Notary Public, personally appeared Constance Yeung, personally known to me or proved to me on the basis of satisfactory evidence, to be the person whose name is subscribed to the within instrument and acknowledged to me that she executed the same in her authorized capacity, and that by her signature on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.

*Ann E. Sherry*

Signature of Notary Public



Place Notary Seal Above

My Commission Expires: April 9, 2021

## EXHIBIT A

Application No.	Filing Date	Patent No.	Issue Date	Cntry	Title
60.947291	6.29.2007	-	-	US	COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
12.164.762	6.30.2008	8,293,752	10/23/2012	US	COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
13.657.506	10.22.2012	8,802,657	8.12.2014	US	COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
14.444.007	7.28.2014	9,556,177	1.31.2017	US	SUBSTITUTED 1,3-TIAZOLES AS SYNTHETIC INTERMEDIATES FOR PREPARATION OF RAF KINASE INHIBITORS
15.380.515	12.15.2016	9,920,048	3.20.2018	US	SUBSTITUTED PYRIMIDINES FOR INHIBITING RAF KINASE ACTIVITY
PCT US2008/068762	6.30.2008	-	-	WO	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
08772238.5	6.30.2008	2167489	5.3.2017	EP	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
08772238.5	6.30.2008	2167489	5.3.2017	DE	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
08772238.5	6.30.2008	2167489	5.3.2017	FR	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
08772238.5	6.30.2008	2167489	5.3.2017	GB	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
8772238.5	6.30.2008	2167489	5.3.2017	CH	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
08772238.5	6.30.2008	2167489	5.3.2017	ES	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
08772238.5	6.30.2008	2167489	5.3.2017	IT	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
2008273002	6.30.2008	2008273002	5.8.2014	AU	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS

Application No.	Filing Date	Patent No.	Issue Date	Cntry	Title
PI0813499-5	6.30/2008	-	-	BR	COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
2.693.182	6.30/2008	2.693.182	1 2/2018	CA	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
200880022788.9	6.30/2008	ZL2008800 22788.9	4 20/2016	CN	COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
202835	6.30/2008	202835	4.1 2015	IL	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
613 DELNP 2010	6.30/2008	279878	1 31.2017	IN	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
2010-515219	6 30/2008	5649445	11 21 2014	JP	COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
10-2009-7027037	6 30/2008	10-1650140	8 16/2016	KR	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
MX a 2009/014276	6.30/2008	319319	4 11 2014	MX	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
582352	6.30/2008	582352	10.8.2012	NZ	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
12010500014	6.30/2008	1201050001 4	6.4.2014	PH	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
2009149214	6/30/2008	2492166	9 10/2013	RU	COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
200908633-1	6.30/2008	157900	10.31.2012	SG	COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
2009-09223	6.30 2008	2009-09223	5 28.2014	ZA	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
97124450	6.27 2008	1444379	7.11 2014	TW	COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
P080102801	6-27-2008	AR067354 B1	2 27 2018	AR	COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
01933-2008	6.27 2008	50582	1 14 2015	CL	COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
10107335.7	8.2.2010	HK1143357	5 4.2018	HK	PYRIMIDINE DERIVATIVES USEFUL

Application No.	Filing Date	Patent No.	Issue Date	Cntry	Title
					AS RAF KINASE INHIBITORS
W00200903699	6/30/2008	IDP000047584	9 7 2017	ID	COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
20090013589	6/30/2008	101478	4/10/2013	UA	COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
17168722.1	6/30/2008	3231798	10/9/2019	EP	COMPOUNDS FOR PREPARING RAF KINASE INHIBITORS
17168722.1	6/30/2008	3231798	10/9/2019	DE	COMPOUNDS FOR PREPARING RAF KINASE INHIBITORS
17168722.1	6/30/2008	3231798	10/9/2019	FR	COMPOUNDS FOR PREPARING RAF KINASE INHIBITORS
17168722.1	6/30/2008	3231798	10/9/2019	GB	COMPOUNDS FOR PREPARING RAF KINASE INHIBITORS
17168722.1	6/30/2008	3231798	10/9/2019	BE	COMPOUNDS FOR PREPARING RAF KINASE INHIBITORS
17168722.1	6/30/2008	3231798	10/9/2019	CH	COMPOUNDS FOR PREPARING RAF KINASE INHIBITORS
17168722.1	6/30/2008	3231798	10/9/2019	DK	COMPOUNDS FOR PREPARING RAF KINASE INHIBITORS
17168722.1	6/30/2008	3231798	10/9/2019	ES	COMPOUNDS FOR PREPARING RAF KINASE INHIBITORS
17168722.1	6/30/2008	3231798	10/9/2019	IE	COMPOUNDS FOR PREPARING RAF KINASE INHIBITORS
17168722.1	6/30/2008	3231798	10/9/2019	IT	COMPOUNDS FOR PREPARING RAF KINASE INHIBITORS
17168722.1	6/30/2008	3231798	10/9/2019	NL	COMPOUNDS FOR PREPARING RAF KINASE INHIBITORS
2014200030	3-Jan-14	-	-	AU	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
201410466320.6	6/30/2008	ZL201410466320.6	1/18/2017	CN	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
201611139456.1	6/30/2008	-	-	CN	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
201618002112	6/30/2008	-	-	IN	A METHOD FOR PREPARING A COMPOUND OF FORMULA II-A



Application No.	Filing Date	Patent No.	Issue Date	Cntry	Title
2013-195277	6.30/2008	5962622	7.8.2016	JP	COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
2015-43208	5-Mar-15	-	-	JP	COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
10-2016-7004-171	6.30/2008	10-176-1076	7.26/2017	KR	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
11195	6.27.2008	GC0009442	12.31.2018	GCC	COMPOUNDS USEFUL AS RAF
2008-001277	6.27.2008	-	-	VE	COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
61.970.595	3.26.2014	-	-	US	PHARMACEUTICAL FORMULATIONS, PROCESSES FOR PREPARATION, AND METHODS OF USE
62.048.527	9.10/2014	-	-	US	PHARMACEUTICAL FORMULATIONS, PROCESSES FOR PREPARATION, AND METHODS OF USE
201691918	3.26.2015	31190	11.30/2018	BY	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
201691918	3.26.2015	31190	11.30/2018	AM	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
201691918	3.26.2015	31190	11.30/2018	AZ	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
201691918	3.26.2015	31190	11.30/2018	KG	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
201691918	3.26.2015	31190	11.30/2018	KZ	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR

Application No.	Filing Date	Patent No.	Issue Date	Cntry	Title
					PREPARATION, AND METHODS OF USE
201691918	3.26.2015	31190	11.30.2018	TJ	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
201691918	3.26.2015	31190	11.30.2018	TM	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
LAP20160441	3.26.2015	-	-	UZ	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
AP2015014304	3.26.2015	P20186932 B	12.4.2018	GE	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
1-2016-04022	3.26.2015	-	-	VN	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
201691918	3.26.2015	31190	11.30.2018	EA	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
PCT US15 22792	3.26.2015	-	-	WO	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
15716288.4	3.26.2015	3122334	6.26.2019	EP	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE

Application No.	Filing Date	Patent No.	Issue Date	Cntry	Title
15716288.4	3 26 2015	3122334	6 26 2019	DE	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR. PROCESSES FOR THEIR PREPARATION. AND METHODS OF USE
15716288.4	3 26 2015	3122334	6 26 2019	FR	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR. PROCESSES FOR THEIR PREPARATION. AND METHODS OF USE
15716288.4	3 26 2015	3122334	6 26 2019	GB	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR. PROCESSES FOR THEIR PREPARATION. AND METHODS OF USE
15716288.4	3 26 2015	3122334	6 26 2019	BE	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR. PROCESSES FOR THEIR PREPARATION. AND METHODS OF USE
15716288.4	3 26 2015	3122334	6 26 2019	CH	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR. PROCESSES FOR THEIR PREPARATION. AND METHODS OF USE
15716288.4	3 26 2015	3122334	6 26 2019	CZ	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR. PROCESSES FOR THEIR PREPARATION. AND METHODS OF USE
15716288.4	3 26 2015	3122334	6 26 2019	ES	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR. PROCESSES FOR THEIR PREPARATION. AND METHODS OF USE
15716288.4	3 26 2015	3122334	6 26 2019	IE	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR. PROCESSES FOR THEIR PREPARATION. AND METHODS OF USE

Application No.	Filing Date	Patent No.	Issue Date	Cntry	Title
15716288.4	3/26/2015	3122334	6/26/2019	IT	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
15716288.4	3/26/2015	3122334	6/26/2019	LU	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
15716288.4	3/26/2015	3122334	6/26/2019	MC	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
BR112016022219-9	3/26/2015	-	-	BR	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
2.943.808	3/26/2015	-	-	CA	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
201580026318.X	3/26/2015	-	-	CN	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
20160000483	3/26/2015	-	-	CR	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
201617034669	3/26/2015	-	-	IN	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE

Application No.	Filing Date	Patent No.	Issue Date	Cntry	Title
2016-558714	3 26.2015	JP6571105	9 4 2019	JP	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
201691918	3 26.2015	31190	11 30.2018	RU	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
15.128.714	9 23.2016	10.426.782	10/1 2019	US	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR AND PROCESSES FOR THEIR PREPARATION
1601005666	3 26.2015	-	-	TH	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
17107610.6	8 1/2017	1233927	2 9.2018	HK	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
PI2016703505	3 26.2015	-	-	MY	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
P00201605735	3 26.2015	-	-	ID	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
1728-2016	3 26.2015	-	-	PE	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
171-2017 DIN	3 26.2015	-	-	PE	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES

Application No.	Filing Date	Patent No.	Issue Date	Cntry	Title
					FOR THEIR PREPARATION, AND METHODS OF USE
160534	3 26 2015	9781	1 30 2018	DZ	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
86/2015	3/26/2015	-	-	BD	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
2016/0003340	3 26 2015	-	-	CO	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
IEPI-2016-84317	3 26 2015	-	-	EC	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
PCT1570/2016	3-26-2015	-	-	EG	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
55 2015	3 26 2015	-	-	JO	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
1151	3 26 2015	10597	3 26 2015	LB	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
15716288.4	3-26-2015	3122334	6 26 2019	MA	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE

Application No.	Filing Date	Patent No.	Issue Date	Cntry	Title
162 2015	3 25 2015	-	-	PK	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR. PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
IN2016/0383	3 26 2015	-	-	TN	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR. PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
20150036046	3 25 2015	-	-	UY	PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR. PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
62.096.020	12.23 2014	-	-	US	COMBINATION OF RAF INHIBITORS AND AURORA KINASE INHIBITORS
PCT US2015-067459	12.22 2015	-	-	WO	COMBINATION OF RAF INHIBITORS AND AURORA KINASE INHIBITORS
15874329.4	12.22.2015	-	-	EP	COMBINATION OF RAF INHIBITORS AND AURORA KINASE INHIBITORS
2,972.076	12.22.2015	-	-	CA	COMBINATION OF RAF INHIBITORS AND AURORA KINASE INHIBITORS
201580073520.8	12.22.2015	-	-	CN	COMBINATION OF RAF INHIBITORS AND AURORA KINASE INHIBITORS
2017-533856	12.22 2015	-	-	JP	COMBINATION OF RAF INHIBITORS AND AURORA KINASE INHIBITORS
15 539.183	6.23 2017	-	-	US	COMBINATION OF RAF INHIBITORS AND AURORA KINASE INHIBITORS
62.242629	10/16 2015	-	-	US	COMBINATION OF RAF INHIBITORS AND TAXANES
PCT US2015 067462	12.22.2015	-	-	WO	COMBINATION OF RAF INHIBITORS AND TAXANES
15874331.0	12.22.2015	-	-	EP	COMBINATION OF RAF INHIBITORS AND TAXANES

Application No.	Filing Date	Patent No.	Issue Date	Cntry	Title
2,972,189	12.22.2015	-	-	CA	COMBINATION OF RAF INHIBITORS AND TAXANES
201580073526.5	12.22.2015	-	-	CN	COMBINATION OF RAF INHIBITORS AND TAXANES
2017-533810	12.22.2015	-	-	JP	COMBINATION OF RAF INHIBITORS AND TAXANES
15 539,185	5 23.2017	-	-	US	COMBINATION OF RAF INHIBITORS AND TAXANES
62 941,426	11 27.2019	-	-	US	SOLID DISPERSION OF PAN-
201992709	11 29.2019	-	-	EA	METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND
PCT/IB2018/053822	5 29 2018	-	-	WO	METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND
18808978.3	11 27 2019	-	-	EP	METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND
2018276192	11 29/2019	-	-	AU	METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND
11 2019 025355 6	11 29 2019	-	-	BR	METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND
3,065,683	11.29 2019	-	-	CA	METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND
IBD	11 29 2019	-	-	CN	METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND
270983	11 27 2019	-	-	IL	METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND
201917051385	11 29 2019	-	-	IN	METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND
JP2017106280	5 30 2017	-	-	JP	METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND
JP2018-103970	5 29 2018	-	-	JP	METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND



Application No.	Filing Date	Patent No.	Issue Date	Cntry	Title
2019-7038460	11 29 2019	-	-	KR	METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND
11201911451T	11 29 2019	-	-	SG	METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND
16/617.914		-	-	US	METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND
MX/a/2019/014256	11 29 2019	-	-	MX	METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND